X-ray Microbeam Irradiation for Peripheral Nerve Demyelination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective treatments for damaged peripheral nerves, particularly due to the scarcity of schwann cell progenitors and the absence of demyelination and remyelination processes similar to those in the central nervous system, making recovery from mechanical, radiation, or autoimmune damage challenging.
Innovation Solution
The method involves irradiating damaged peripheral nerves with an array of x-ray microbeams to initiate demyelination, followed by administering schwann cell progenitors to stimulate new myelin production, potentially using adult rat olfactory sphere cells or neural stem cells, and repeating the process to achieve full remyelination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional radiation therapy is used to treat damaged peripheral nerves, then some tissue damage is reduced, but the scarcity of schwann cell progenitors prevents effective remyelination
Solution Approach 1:
The patent applies preliminary action by first irradiating the damaged peripheral nerve with x-ray microbeams to initiate demyelination and create a receptive environment, before administering schwann cell progenitors to facilitate remyelination. This sequential approach ensures the tissue is prepared in advance to receive and utilize the administered cells effectively.
Solution Approach 2:
The patent uses x-ray microbeam irradiation as an intermediary process between the damaged nerve and the administered schwann cell progenitors. The microbeam irradiation modifies the tissue environment to make it receptive to the progenitors, acting as a mediator that enables the subsequent remyelination process.
2Productivity
If high dose radiation is applied to initiate demyelination, then myelin removal is effective, but surrounding healthy tissue is damaged
Solution Approach 1:
The patent segments the radiation delivery into discrete microbeams rather than applying a continuous broad beam. Each microbeam is targeted at specific locations along the peripheral nerve to initiate localized demyelination, while the spaces between microbeams preserve surrounding healthy tissue from excessive radiation exposure.
Solution Approach 2:
The patent applies local quality by delivering radiation in a non-uniform pattern where only specific localized regions receive high-dose microbeam irradiation for demyelination, while adjacent regions receive minimal or no radiation, maintaining their healthy state. This creates spatially varying radiation doses tailored to treatment needs.
Data Source
AI summary
A method for treating damaged peripheral nerves of a subject includes irradiating at least a portion of the damaged PNs with an array of x-ray microbeams having an in-beam dose sufficient to at least initiate demyelination, each of the microbeams being no greater than 0.7 mm in thickness, and separated for tissue sparing, e.g., by at least 0.05 mm, and optionally administering schwann cell progenitors (SCPs) to the irradiated portion to remyelination before or after irradiating. In-beam dose may be between about 30 to 200 Gy. The method may include irradiating using an x-ray tube of a CT scanner having a multi-aperture collimator mounted thereto and on/near the subject. The SCPs may be adult rat olfactory sphere cells or neural stem cells.